Chardan Acts as Exclusive Placement Agent in Forge Biologics $120 Million Series B Financing
Funds raised to accelerate expansion of AAV manufacturing CDMO capabilities and advance novel gene therapy pipeline
News provided by
Share this article
Share this article
NEW YORK, April 29, 2021 /PRNewswire/ Chardan, a global investment bank, today announced that it acted as exclusive placement agent in the successful closing of $120 million Series B financing of Forge Biologics, a gene therapy-focused contract development and manufacturing organization. We are delighted to support the outstanding team of Forge in the goal of raising capital to further accelerate the expansion of their AAV manufacturing CDMO capabilities, while advancing novel AAV gene therapy programs to provide broader access to life-saving therapies, said Murat Omur, Chardan s Head of Healthcare Investment Banking.